A t present, the standard treatment for locally advanced breast cancer is neoadjuvant chemotherapy facilitating lesion regression, tumor down-staging, less disfiguring surgery, stronger local control, and higher rate of breast conservation. 1 While almost all populations of patients with breast cancer benefit from chemotherapy, 2 molecular prognostic and predictive factors of response or resistance are lacking in clinical practice to guide the selection of patients for chemotherapy. The expression status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2), and Ki-67 are the main indexes for breast cancer molecular classification and prognosis, and the chemotherapy regimens are mainly based on the presence of these indexs status on the core needle biopsy prior to treatment. However, the previous studies indicated considerable controversy referring to the change of ER, PR, Her-2, and Ki-67 expression status in relation to neoadjuvant chemotherapy. In addition, it is not well-known whether these biomarkers change after neoadjuvant chemotherapy, requiring a change in further adjuvant systemic treatment. This research retrospectively analyzed ER, PR, Her-2, and Ki-67 expressions in 103 breast cancer patients pre and post-neoadjuvant chemotherapy, aiming to investigate the effects of neoadjuvant chemotherapy on these factors and explore its clinical value.
METHODS

Study population
One hundred and three patients newly diagnosed with breast cancer between October 2010 and February 2013 at the Affiliated Tumor Hospital of Guangxi Medical University (Nanning, China) without metastases pre-chemotherapy were included in our study. All patients were females, aged from 22 to 66 (median age 46 years). Of the 103 patients, one was bilateral primary, two were unilateral multi-centric breast cancer, and the rest were unilateral cases. While 100 patients had infiltrating ductal carcinomas, three had infiltrating lobular carcinomas. Full tumor assessments were performed by mammography, ultrasoundgraphy, computed tomography scans, or magnetic resonance imaging scans. According to TNM classification of UICC, 47 patients were diagnosed with stage II and 56 with stage III.
Methods
Core needle (BARD, New Jersey,USA) biopsy of the primary lesion was performed before chemotherapy. Sections were cut and stained with hematoxylin-eosin (HE) for histopathological diagnosis. Specimens were tested for ER, PR, Her-2, and Ki-67 expressions by immunohistochemical staining using an EnVision+ (DAKO, USA) protocol. Neoadjuvant chemotherapy was assigned to each patient according to their risk on the basis of clinical parameters and also in accordance with the recommendation of the St Gallen International Expert Consensus. The neoadjuvant chemotherapy included FAC/ FEC regimen (5-fluorouracil, 500 mg/m 2 , day 1 (d1); cyclophosphamide, 500 mg/m 2 , d1; and pirarubicin, 50 mg/m 2 , d1 or epirubicin, 100 mg/m 2 , d1) and TAC/TEC regimen (docetaxel, 75 mg/m 2 ; clophosphamide, 500 mg/ m 2 , d1; pirarubicin, 50 mg/m 2 , d1 or epirubicin, 100 mg/ m 2 , d1), for a median of three cycles (range 2-6 cycles). The cycles of neoadjuvant chemotherapy were according to the clinical response and the assessment of physicians; once the opportunity for modified radical mastectomy or breast-conserving surgery was got, neochemotherapy was terminated and surgical operation was conducted. 3 All the patients underwent mastectomy or breast-conserving surgery plus axillary lymph node dissection within four weeks after neoadjuvant chemotherapy at the Affiliated Tumor Hospital of Guangxi Medical University. Postchemotherapy specimens were obtained during surgery and subjected to immunohistochemical analyses of ER, PR, Her-2, and Ki-67 expressions.
Assessment of response to neoadjuvant chemotherapy
Treatment responses were classified according to the response evaluation criteria in solid tumor (RECIST) methodology as follows: no clinical evidence of tumor in the breast and axillary lymph nodes was defined as a complete response (CR). Reduction in the greatest tumor diameter exceeded 30% was graded as a partial response (PR). Tumor reduction less than 30% or an increase up to 20% in the greatest diameter was considered as a stable disease (SD). Tumors with increase of more than 20% in the greatest diameter or appearance of new disease were considered as a progressive disease (PD). In the surgical specimen, pathologic responses were evaluated according to the criteria of Kuerer et al. 4 In particular, the achievement of pathologic complete response (pCR) on postoperative specimens was defined as the absence of invasive residuals in breast or nodes.
Immunohistochemistry
All tissue specimens were routinely fixed in 10% neutralbuffered formalin and embedded in paraffin. Briefly, 3-μm-thick sections were cut from paraffin blocks containing representative tumor samples. Paraffin sections were dewaxed in xylene, rehydrated through a series of graded alcohols, placed in 10 mm citrate buffer, and submitted to heat retrieval using a vapor lock for 40 minutes. After heating, the slides were allowed to cool to room temperature and briefly washed with Tris-buffered saline. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol for five minutes. Normal serum (Novostain Super ABC kit, Novocastra, Newcastle upon Tyne, UK) was used for 30 minutes in order to block non-specific immunoassaying. Immunohistochemical staining was performed using an avidin-biotin peroxidase system (Novostain Super ABC kit, Novocastra). Following washes in PBS, biotinylated universal secondary antibody (Novostain Super ABC kit) was applied for 30 minutes. The sections were incubated with the avidin-biotin complex reagent (Novostain Super ABC kit) for 30 minutes and developed with 3,3-diaminobenzidine tetrahydrochloride (DAB) in phosphate-buffered saline, pH 7.5, containing 0.036% hydrogen peroxide for 5 minutes. Light Mayer's hematoxylin was applied as a counterstain. The slides were then dehydrated in a series of ethanol and mounted with permount (Fischer, Fairlawn, NJ, USA).
Scoring methods
Stained with diaminobenzidine, observed under a light microscope, an EnVision+ (DAKO, Glostrup, Denmark) protocol was performed to detect the expressions of ER, PR, Her-2, and Ki-67. The results were scored incorporating both the percentages of positively stained tumor cells and staining intensity. Ten randomized high-power fields were chosen to evaluate the intensity denoted as 0 (no staining), 1 (light yellow), and 2 (brown or dark brown). HSCORE was calculated by the sum of the percentages of cells staining intensity multiplied by the weighted intensity of staining. Localized on cell nucleus, ER or PR that presented brownish yellow was considered positivity on a scale of negative to 4+. Cases were reported negative if positive tumor cell less than 5% was seen, 1+ if from 5% to 25%, 2+ if from 26% to 50%, 3+ if from 51% to 75%, and 4+ if more than 75%. Localized on cytomembranes and their cytoplasm, Her-2 that presented brownish yellow was considered positivity. Her-2-positive tumors were defined as those scoring 3+ with IHC staining or testing positive by ISH. Her-2-negative tumors were defined as those scoring 0 to 1+ with IHC or scoring 2+ with IHC and testing negative by ISH. Ki-67 protein that mapped in the nucleus of cells and stained brownish yellow was recorded as the proportion of positive tumor cells per high-power fields. Ki-67 was scored as the percentage of nuclear-stained cells out of all cancer cells in the invasive front of the tumor regardless of the intensity in 400× high-power fields; 500-1 000 tumor cells were counted in each case.
Statistical analysis
Statistical analysis was performed by SPSS 17.0 Program (SPSS Inc, Chicago, IL, USA). The comparison of ER, PR, and Her-2 pre-and post-neoadjuvant chemotherapy was assessed by the χ 2 test and Ki-67 was assessed by t-test. Correlations of Ki-67 expression with molecular subtypes or chemotherapy response were evaluated using the χ 2 test. P-values less than 0.05 were considered statistically significant.
RESULTS
Patient and tumor characteristics
The patient and tumor characteristics are summarized in Table 1 . Of the 103 neoadjuvant chemotherapy administered patients, 4.9% (5/103) achieved a CR, 79.6% (82/103) experienced PR, 14.6% (15/103) SD, and 0.9% (1/103) underwent PD, resulting in the response rate (CR+PR) of 84.5%. The pCR was 8.7% (9/103). Of the 103 carcinomas studied, 100 cases were infiltrating ductal carcinomas and three were lobular. The median age of the patients was 45 years (range 22-67 years), and 62.1% of these patients were premenopausal. In terms of clinical evaluation, 45.6% of studied patients prior to neoadjuvant chemotherapy were stage II (47/103) and 54.4% were stage III (56/103).
Effects of neoadjuvant chemotherapy on ER, PR, Her-2, and Ki-67 expressions
The ER, PR, Her-2, and Ki-67 status were retested by using IHC of the operation specimens in 94 patients with residual invasive carcinoma. Among the 94 patients who did not achieve pCR, the expression status of ER and PR pre-and post-chemotherapy were, respectively, changed in 14.9% (14/94) and 21.3% (20/94) patients. In addition, the change of Her-2 expression status was observed in 25.5% (24/94) patients. This difference, however, was not statistically significant (Table 2 ). According to regimens of neoadjuvant chemotherapy, all patients were assigned to either anthracyclines-containing regimen (FAC/FEC) or taxanes-based regimen (TAC/TEC). The expression changes of ER, PR, and Her-2 pre-and post-chemotherapy in the two groups were not significantly different ( Table  2 ). Before chemotherapy, the mean score of Ki-67 was 39.7%, and it decreased to 24.1% after chemotherapy, and the change of Ki-67 index was statistically significant (P <0.001). Both chemotherapy regimens decreased the mean level of Ki-67 expression, but the decrease was more pronounced in taxanes-based regimen group (Table 3) . We further analyzed whether the changes of Ki-67 index was associated with breast cancer molecular subtypes. The ). Statistical analysis showed that the difference was statistically significant among these four subtypes ( Table 4 ).
The correlation between changes of Ki-67 and chemotherapeutic effect
Since the change of Ki-67 index was statistically significant, we next examined whether the change of Ki-67 could predict the response to neoadjuvant chemotherapy. In this study, the average value of Ki-67 decreased from 39.7% to 24.1% after the administration of chemotherapy (P <0.001). Patients that responded to the chemotherapy (PR+CR) showed more dramatic decrease of Ki-67 level: 39.3% before treatment to 22% afterwards (P <0.001).
Meanwhile, this kind of significant decrease was not found in patients that did not responde to the chemotherapy (SD+PD), with 41.3% of Ki-67 level before chemotherapy compared to 37% after chemotherapy (P = 0.466). After neoadjuvant chemotherapy, 49 patients displayed obvious Ki-67 decrease. The clinical response rate (PR+CR) was higher in the Ki-67 decreased patients (96%), compared with patients whose Ki-67 expression did not decrease (62%). Besides, tumors with Ki-67 decrease showed significantly improved pCR rates. The difference between each group was statistically significant (P <0.001, Table 5 ).
DISCUSSION
Currently, patients of breast cancer presenting with large primary lesions, metastases of axillary lymph node, or high risk of recurrence or metastases could benefit from neoadjuvant chemotherapy to reduce the size of an initially unresectable tumor or convert the planned surgery from mastectomy to breast conservation. However, no predictive markers were identified for neoadjuvant chemotherapy. In order to avoid overtreatment, predicting the response to neoadjuvant chemotherapy is crucial for patients before the start of chemotherapy. The exploration of a reliable predictive factor for neoadjuvant chemotherapy in breast cancer remains a challenge. And up to now, the effect of chemotherapy on the pathological and biological factors is contradictive. At present, detection of ER, PR, Her-2, and Ki-67 expressions provide crude estimates of risk of relapse, guide adjuvant chemotherapy and endocrine therapy. This study analyzed the expression status of ER, PR, Her-2, and Ki-67 in patients with breast cancer pre-and post-neoadjuvant chemotherapy to demonstrate the effect of chemotherapy on those parameters.
As a distinct biomarker of cell proliferation, Ki-67 is used as a reliable indicator to monitor tumor cell proliferation activity. 5 With a definite correlation to mitotic rate, Ki-67 predicts tumor progression, metastases, and outcome. 6 At present, it is confirmed that there is a positive relationship between the Ki-67 and Her-2 expressions and tumor malignancy, with the coexpression of Ki-67 and Her-2 indicating more aggressive and poor prognosis. 7 Several reports have shown cutoff level of Ki-67 expression after chemotherapy. [8] [9] [10] [11] Besides conduction cell apoptosis induction to kill tumor cell, the majority of chemotherapy drugs including anthracyclines and taxanes depress cell proliferation to suppress tumor progression. As the most widely used biomarker to measure the tumor cell proliferation index, Ki-67 clearly indicates the status of tumor proliferation. The more sensitive to the chemotherapy, the more pronounced the decreased level of Ki-67. Our research indicated that neoadjuvant chemotherapy cut off the Ki-67 index, which was associated with chemotherapy efficacy. Therefore Ki-67 could be considered as a predictive factor of neoadjuvant chemotherapy. 12 ER and PR are proteins with the specific function of moderating breast cancer proliferation and differentiation. Patients with tumors that express ER or PR are sensitive to endocrine therapy and predictive better prognosis, and vice versa. 13, 14 Therefore, the evaluation of prognosis and guidance of endocrine therapy for breast cancer by ER and PR tests are of great clinical value. Currently, there is lack of consensus regarding whether there are changes in ER and PR expression status in breast cancer patients receiving neoadjuvant chemotherapy. Van de Ven et al 14 pooled 32 studies for retrospective analysis and reported that the rates of ER and PR expression changes pre-and post-neoadjuvant chemotherapy were 2.5%-17.0% and 5.9%-51.7%, respectively. Neubauer et al 8 also supported that the administration of neoadjuvant chemotherapy changed ER and PR status. Kasami et al 15 showed that the difference in ER status pre and post-neoadjuvant chemotherapy was not significant; conversely, PR status changed. In this research, of the total 94 cases undergoing immunohistochemical analysis, before chemotherapy, 74 cases (78.7%) positively expressed ER and 61 cases (63.1%) were PR positive, whereas after chemotherapy, 72 cases (76.6%) were ER positive and 55 cases (58.5%) were PR positive, indicating no significant difference in ER and PR status before and after neoadjuvant chemotherapy. We concluded that neoadjuvant chemotherapy did not affect ER and PR status, that was, chemotherapy just depressed tumor progression and inducted apoptosis to shrink tumors, but did not change hormone receptor status. Therefore, the determination of endocrine therapy for clinician is confirmed according to the ER and PR status tested before neoadjuvant chemotherapy. Although ER and PR status may be transformed from positive to negative in a minority of patients post-neoadjuvant chemotherapy, they should be recommended for endocrine therapy as well. If necessary, re-detection should be performed on the specimen obtained pre-chemotherapy before making treatment strategy plan with caution.
As an independent prognostic factor, overexpression of Her-2 is associated with great malignancy and impaired survival. [16] [17] [18] [19] Whether neoadjuvant chemotherapy containing anthracyclines and taxanes changes the amplification and overexpression of Her-2 is controversial. While most reports 20 demonstrated a stable expression status pre and post-neoadjuvant chemotherapy, Her-2 expression level was shown to be decreased or elevated by other researches. 21 In our study, the rates of positive Her-2 expression were 60.6% (57/94) and 27.7% (26/94) prechemotherapy, respectively, and 64.9% (61/94) and 29.8% (28/94), respectively, post-chemotherapy, with no statistical differences. This result indicated no significant effect of neoadjuvant chemotherapy on Her-2-positive rate and overexpression in breast cancer, 22 which might be explained by the theory that Her-2 was not the therapy target of the commonly used chemotherapy drugs. Herceptin as secondline therapy for treatment in Her-2/neu-overexpressing tumors is retained after neoadjuvant chemotherapy.
As a cell cycle non-specific agent, anthracyclines inhibit DNA and RNA syntheses by intercalating between base pairs of the DNA/RNA strand, thus preventing the replication of rapidly growing cancer cells. Conversely, taxanes are cell cycle-specific agents, playing an anticancer role by disrupting microtubule function which is essential to mitosis and arresting cells at the G2/M phase of the cell cycle to kill tumor cell. Virtually with no cross-resistance existing, these two kinds of drugs could be administrated alone or combined for chemotherapy of breast cancer. 23 Hence these drugs should be recommended for first-line treatment of breast cancer. This study divided patients into regimen containing anthracyclines alone and regimen containing anthracyclines combined with taxanes. This study showed that after 2-4 cycles of chemotherapy, patients of both groups achieved certain therapeutic effect. The ER, PR, and Her-2 status in the two groups did not changed pre-and post-chemotherapy. But the Ki-67 value in both groups decreased and was more significant in anthracyclines plus taxanes regimen group, and thus we came to the conclusion that anthracyclines combined with taxanes were more likely to depress proliferation of cancer cells and stronger for tumor control.
The limitation of this research is that the existence of tumor heterogeneity has led to concerns that core biopsies may not be representative of the tumor tissue as a whole as they are often restricted to the superficial aspects of the tumor. So, the expression status of ER, PR, Her-2, and Ki-67 may be caused by the one-sidedness of puncture which we performed multiple punch biopsy to avoid. Nevertheless, the false-negative expression is theoretically inevitable.
In conclusion, no significant difference was identified in ER, PR, or Her-2 expressions pre-and post-neoadjuvant chemotherapy. However, there was a statistically significant decrease in Ki-67 proliferation index following neoadjuvant chemotherapy. The change in Ki-67 was correlated with molecular subtypes and also with response to neoadjuvant chemotherapy. According to the ER, PR, Her-2, and Ki-67 expression status, therapy strategy for breast cancer is tailored on an individual patient basis. Ki-67 index is a surrogate marker to predict the treatment response of neoadjuvant chemotherapy, but requires further investigation.
